EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mechanisms of resistance to EGFR-targeted therapies in colorectal cancer: more than just genetics

Christine Parseghian, Madhulika Eluri, Scott Kopetz, Kanwal Raghav

Frontiers in Cell and Developmental Biology · 15.09.2023 · 11

DOI: 10.3389/fcell.2023.1176657 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 15.09.2023. Verfasst von Christine Parseghian und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of acquired resistance to anti-EGFR therapies remains poorly understood, with most research to date exploring, and trying to overcome, various genomic mechanisms of resistance. However, recent work supports a model of resistance whereby transcriptomic mechanisms of resistance predominate in the presence of active cytotoxic chemotherapy combined with anti-EGFR therapy in the first-line setting, with a greater predominance of acquired MAPK mutations after single-agent anti-EGFR therapy in the later-line setting. The proposed model has implications for prospective studies evaluating anti-EGFR rechallenge strategies guided by acquired MAPK mutations and highlights the need to address transcriptional mechanisms of resistance.

Schlagwörter

Stichwörter der Autor:innen

anti-EGFRanti-EGFR rechallengeanti-EGFR resistancegenomic mechanisms of resistance to anti-EGFRnon-genomic mechanisms of resistance to anti-EGFR

Autor:innen und Institutionen

  • Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
  • Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Zitieren

APA

Parseghian, C., Eluri, M., Kopetz, S., & Raghav, K. (2023). Mechanisms of resistance to EGFR-targeted therapies in colorectal cancer: more than just genetics. Frontiers in Cell and Developmental Biology, 11. https://doi.org/10.3389/fcell.2023.1176657

Vancouver

Parseghian C, Eluri M, Kopetz S, Raghav K. Mechanisms of resistance to EGFR-targeted therapies in colorectal cancer: more than just genetics. Frontiers in Cell and Developmental Biology. 2023;11. doi:10.3389/fcell.2023.1176657

BibTeX
@article{Parseghian2023,
  author = {Parseghian, Christine and Eluri, Madhulika and Kopetz, Scott and Raghav, Kanwal},
  title = {Mechanisms of resistance to EGFR-targeted therapies in colorectal cancer: more than just genetics},
  journal = {Frontiers in Cell and Developmental Biology},
  year = {2023},
  volume = {11},
  doi = {10.3389/fcell.2023.1176657}
}
Kostenlos starten →